Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study

[1]  B. Lewis,et al.  Visceral abdominal adipose tissue and coronary atherosclerosis in asymptomatic diabetics. , 2013, International journal of cardiology.

[2]  S. Anker,et al.  Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. , 2012, International journal of cardiology.

[3]  M. Febbraio,et al.  Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.

[4]  J. Moreno-Navarrete,et al.  CD14 Modulates Inflammation-Driven Insulin Resistance , 2011, Diabetes.

[5]  W. Cefalu.  Fractalkine: A Cellular Link Between Adipose Tissue Inflammation and Vascular Pathologies , 2011, Diabetes.

[6]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[7]  G. Doronzo,et al.  Adipocytokines in Atherothrombosis: Focus on Platelets and Vascular Smooth Muscle Cells , 2010, Mediators of inflammation.

[8]  S. Kaul,et al.  Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. , 2010, Circulation.

[9]  K. Jablonski,et al.  The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes , 2010, Annals of Internal Medicine.

[10]  Y. Wan,et al.  Rosiglitazone activation of PPARγ suppresses fractalkine signaling , 2009, Journal of molecular endocrinology.

[11]  T. Kato,et al.  Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[12]  K. Hara,et al.  Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. , 2009, Diabetes research and clinical practice.

[13]  R. DeFronzo,et al.  Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans , 2009, Diabetologia.

[14]  D. Levy,et al.  Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005 , 2009, Circulation.

[15]  D. Levy,et al.  Trends in All-Cause and Cardiovascular Disease Mortality among Women and Men with and without Diabetes in the Framingham Heart Study, 1950-2005 , 2009 .

[16]  R. Koenen,et al.  High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells , 2008, Thrombosis and Haemostasis.

[17]  J. Zierath,et al.  siRNA-Mediated Reduction of Inhibitor of Nuclear Factor-κB Kinase Prevents Tumor Necrosis Factor-α–Induced Insulin Resistance in Human Skeletal Muscle , 2008, Diabetes.

[18]  S. Lira,et al.  Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2−/− Mice: Evidence for Independent Chemokine Functions in Atherogenesis , 2008, Circulation.

[19]  K. Cusi,et al.  Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. , 2007, Journal of hepatology.

[20]  M. Hanefeld,et al.  Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. , 2007, Journal of the American College of Cardiology.

[21]  R. Virmani,et al.  Pioglitazone Inhibits In-Stent Restenosis in Atherosclerotic Rabbits by Targeting Transforming Growth Factor-&bgr; and MCP-1 , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[22]  M. Matsuda,et al.  Thiazolidinediones improve beta-cell function in type 2 diabetic patients. , 2007, American journal of physiology. Endocrinology and metabolism.

[23]  S. Sasaki,et al.  Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance , 2007, Heart and Vessels.

[24]  R. Buckingham,et al.  Effect of various diuretic treatments on rosiglitazone-induced fluid retention. , 2006, Journal of the American Society of Nephrology : JASN.

[25]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[26]  D. Accili,et al.  Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. , 2005, The Journal of clinical investigation.

[27]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[28]  G. Sesti,et al.  C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. , 2005, Diabetes care.

[29]  M. Hanefeld,et al.  Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes , 2005, Diabetologia.

[30]  R. DeFronzo,et al.  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. , 2004, Archives of internal medicine.

[31]  R. DeFronzo,et al.  Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.

[32]  G. Oster,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.

[33]  R. Black,et al.  A Continuous Fluorimetric Assay for Tumor Necrosis Factor-α Converting Enzyme , 2002 .

[34]  R. Black,et al.  A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme. , 2002, Analytical biochemistry.

[35]  M. Matsuda,et al.  Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.

[36]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[37]  M. Rewers,et al.  Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. , 1999, Diabetes care.

[38]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[39]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[40]  R. Hovorka,et al.  ISEC: a program to calculate insulin secretion. , 1996, Computer methods and programs in biomedicine.

[41]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[42]  R. DeFronzo,et al.  Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. , 1993, The Journal of clinical investigation.

[43]  R. N. Bergman,et al.  Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study , 1992, The Lancet.

[44]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.